FR2532178B1 - Procede pour stabiliser le facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur - Google Patents

Procede pour stabiliser le facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur

Info

Publication number
FR2532178B1
FR2532178B1 FR8313971A FR8313971A FR2532178B1 FR 2532178 B1 FR2532178 B1 FR 2532178B1 FR 8313971 A FR8313971 A FR 8313971A FR 8313971 A FR8313971 A FR 8313971A FR 2532178 B1 FR2532178 B1 FR 2532178B1
Authority
FR
France
Prior art keywords
factor
stabilizing
tumor necrosis
tnf
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8313971A
Other languages
English (en)
Other versions
FR2532178A1 (fr
Inventor
Hiroshi Hayashi
Masanobu Komiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP57149890A external-priority patent/JPS5939829A/ja
Priority claimed from JP57172178A external-priority patent/JPS5959625A/ja
Application filed by Asahi Chemical Industry Co Ltd, Asahi Kasei Kogyo KK filed Critical Asahi Chemical Industry Co Ltd
Publication of FR2532178A1 publication Critical patent/FR2532178A1/fr
Application granted granted Critical
Publication of FR2532178B1 publication Critical patent/FR2532178B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR8313971A 1982-08-31 1983-08-31 Procede pour stabiliser le facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur Expired FR2532178B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57149890A JPS5939829A (ja) 1982-08-31 1982-08-31 ガン壊死因子安定化法
JP57172178A JPS5959625A (ja) 1982-09-28 1982-09-28 ガン壊死因子を安定化する方法

Publications (2)

Publication Number Publication Date
FR2532178A1 FR2532178A1 (fr) 1984-03-02
FR2532178B1 true FR2532178B1 (fr) 1986-07-04

Family

ID=26479654

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8313971A Expired FR2532178B1 (fr) 1982-08-31 1983-08-31 Procede pour stabiliser le facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur

Country Status (6)

Country Link
US (1) US4457916A (fr)
DE (1) DE3331003C2 (fr)
ES (1) ES8706446A1 (fr)
FR (1) FR2532178B1 (fr)
GB (1) GB2126588B (fr)
IT (1) IT1200970B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
CA1213827A (fr) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Procede de pasteurisation de la fibronectine
GB2187191B (en) * 1984-01-30 1989-11-01 Quadrant Bioresources Ltd Protection of proteins and the like
EP0158487B1 (fr) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Composition stable d'interleukine-2
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US6686455B1 (en) * 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
US5840522A (en) * 1984-09-20 1998-11-24 Chiron Corporation Recombinant lectins
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61108400A (ja) * 1984-10-31 1986-05-27 Amano Pharmaceut Co Ltd コレステロ−ルの定量法
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
EP0193917A3 (fr) * 1985-03-06 1987-09-23 American Cyanamid Company Compositions dispersibles et solubles dans l'eau de polymères pour administration parentérale
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US6084073A (en) * 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE3682047D1 (de) * 1985-07-09 1991-11-21 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US4868108A (en) * 1985-12-12 1989-09-19 Hygeia Sciences, Incorporated Multiple-antibody detection of antigen
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
NL8701143A (nl) * 1986-05-27 1987-12-16 Sandoz Ag Farmaceutische preparaten.
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US4678812A (en) * 1986-05-30 1987-07-07 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
CA1292686C (fr) * 1986-10-27 1991-12-03 Ze'ev Shaked Compositions pharmaceutiques d'interleukine-2 recombinante et procede de fabrication
ATE225509T1 (de) 1987-04-27 2002-10-15 Inverness Medical Switzerland Testgerät zur durchführung von spezifischen bindungsprüfungen
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
CA1327161C (fr) * 1987-09-01 1994-02-22 Mitsugu Kobayashi Composition pharmaceutique lyophilisee d'un derive de neocarzinostatine
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5221616A (en) * 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
USRE38385E1 (en) 1989-02-16 2004-01-13 Nektar Therapeutics Storage of materials
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
TW282399B (fr) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases
AU673827B2 (en) * 1992-03-24 1996-11-28 United Cancer Research Institute Vaccine containing live virus for therapy of viral diseases and malignancies
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
AU689217B2 (en) 1994-03-07 1998-03-26 Novartis Ag Methods and compositions for pulmonary delivery of insulin
EP0763056B1 (fr) * 1994-03-16 2000-08-09 Mallinckrodt Inc. Utilisation de produits tensioactivs pour la stabilisation de peptides et de proteines dans le but d'une utilisation radiopharmaceutique
WO1995033488A1 (fr) * 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Procede prevenant l'aggregation de differentes substances lors de rehydratations et de decongelations, et compositions obtenues
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6080707A (en) * 1995-02-15 2000-06-27 The Procter & Gamble Company Crystalline hydroxy waxes as oil in water stabilizers for skin cleansing liquid composition
BR9607609A (pt) * 1995-02-15 1998-06-09 Procter & Gamble Composição líquida ara limpeza da pele de formação de espuma de intensidade estável e conjunto de banho de asseio do corpo
EP0814765B1 (fr) 1995-03-14 2002-01-23 The Procter & Gamble Company Silice amorphe dispersee servant de stabilisateur huile dans eau pour compositions nettoyantes liquides pour la peau
MX9706954A (es) * 1995-03-14 1997-11-29 Procter & Gamble Barro de esmectita dispersado como estabilizador de aceite en agua para composicion liquida de limpieza para la piel.
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9508691D0 (en) 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5876992A (en) 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6558901B1 (en) 1997-05-02 2003-05-06 Biomerieux Vitek Nucleic acid assays
IL124275A (en) * 1997-05-02 2002-03-10 Bio Merieux Vitek Inc A method to produce sequences of nucleic acids
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
DE19758073A1 (de) * 1997-12-30 1999-07-01 Schleuning Michael Priv Doz Dr Verfahren zur Kryokonservierung menschlicher und tierischer hämatopoetischer Zellen
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
PT1253932E (pt) * 2000-02-08 2005-07-29 Allergan Inc Composicoes farmaceuticas de toxina botulinica
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
ATE526340T1 (de) 2001-10-22 2011-10-15 Dompe Spa Verfahren durch gebrauch von überkritischen flüssigkeiten: herstellung von proteinmikropartikeln und ihre stabilisierung
EP1458360B1 (fr) 2001-12-19 2011-05-11 Novartis AG Administration pulmonaire d'aminoglycosides
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US20040229785A1 (en) * 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
JP5128935B2 (ja) * 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
JP4972081B2 (ja) 2005-03-14 2012-07-11 ワイス・エルエルシー チゲサイクリン組成物および調製方法
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8187799B2 (en) * 2007-04-26 2012-05-29 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
FR2930447B1 (fr) * 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
JP2011520889A (ja) * 2008-05-15 2011-07-21 バクスター・インターナショナル・インコーポレイテッド 安定な医薬製剤
CN102803507B (zh) 2009-06-12 2016-05-25 精密公司 用于微流体装置中在板反应剂的脱水储存的组合物及方法
WO2010144682A1 (fr) 2009-06-12 2010-12-16 Micronics, Inc. Matrices réhydratables pour stockage à sec de la taq polymérase dans un dispositif microfluidique
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
WO2016187068A1 (fr) 2015-05-15 2016-11-24 The General Hospital Corporation Anticorps antagonistes de la superfamille du récepteur du facteur de nécrose anti-tumoral
EP3355914B1 (fr) 2015-09-29 2024-03-06 The General Hospital Corporation Une composition comprenant bcg pour réduire le cholesterol.
KR102410778B1 (ko) 2016-05-13 2022-06-21 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US11666655B2 (en) 2016-11-28 2023-06-06 Indian Institute Of Technology, Delhi Formulation for stabilizing bio-therapeutics
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637640A (en) * 1970-05-04 1972-01-25 Diagnostic Data Inc Orgotein stabilized with saccharide process and products
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
EP0018609B1 (fr) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Solutions aqueuses de protéines, stables à la dénaturation, procédé pour leur fabrication et leur utilisation
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process

Also Published As

Publication number Publication date
FR2532178A1 (fr) 1984-03-02
IT1200970B (it) 1989-01-27
DE3331003C2 (de) 1986-07-10
GB8323271D0 (en) 1983-10-05
US4457916A (en) 1984-07-03
ES525228A0 (es) 1987-06-16
GB2126588A (en) 1984-03-28
ES8706446A1 (es) 1987-06-16
IT8367886A0 (it) 1983-08-23
DE3331003A1 (de) 1984-03-01
GB2126588B (en) 1986-06-25

Similar Documents

Publication Publication Date Title
FR2532178B1 (fr) Procede pour stabiliser le facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur
US3791384A (en) Artificial insemination of sows
ES2100866T3 (es) Tratamiento de frutas.
IE45026L (en) Veterinary compositions
LTIP869A (en) Rodenticidic composition, process for preparing thereof, method for the reduction of rodents population
NL8004801A (nl) Werkwijze en inrichting voor het houdbaar maken van zaad van huisdieren.
ATE141509T1 (de) Verfahren zum lagern von erythrozyten
OA08710A (fr) Sel de sodium de 5-chloro-3-(2-thénoyl)-2-oxindole-1-carboxamide anhydre cristallin, son procédé de préparation et composition pharmaceutique le contenant.
US2433299A (en) Blood coagulant and method of preserving same
SE8701372D0 (sv) Forfarande och medel for konservering av ho
US4736706A (en) Animal litter and process for the production thereof
JPS5765173A (en) Method of freezing fresh food
SU959786A1 (ru) Способ консервировани цельной крови
JPS5959625A (ja) ガン壊死因子を安定化する方法
SE312638B (fr)
Wang et al. Dieldrin, effect on the ion transport activities in liver tissues
SU618363A1 (ru) Способ предотвращени слеживаемости аммиачной селитры
JPS56144046A (en) Loosening agent for frozen fish
GB1366138A (en) Treatment of lignocellulose materials
SU935098A1 (ru) Среда дл разбавлени и замораживани семени сельскохоз йственных животных
DE2154260A1 (de) Verfahren zum konservieren von ebersperma durch tiefgefrieren, auftauen und einbringen in den uterus der sau
RU2013095C1 (ru) Состав для дезинфекции объектов животноводства при минусовых температурах
JPH0317457B2 (fr)
SU1049539A1 (ru) Средство дл сохранени жизнеспособности бактериальной микрофлоры в пробах кала человека
RU2001117041A (ru) Способ деконтаминации веществ